Anti-inflammatory activity of resveratrolin coronary heart disease

Abstract

Treatment of Coronary Heart Disease (CHD) remains an open pressing issue of modern medicine. Worldwide, despite the numerous methods of correction of CHD that are being developed, there has been no improvement in the situation with morbidity and mortality. In developed countries, CHD remains in the first place in the structure of mortality from all causes. In Ukraine over the past decade, CHD accounted for 65-68% of all deaths in the structure of cardiovascular diseases (CVD). Among the able-bodied population in Ukraine, CHD leads to disability in 38.5%, and the average age of patients becomes younger.